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Background: Signal transduction by growth factor
receptor protein-tyrosine kinases is generally initiated by
autophosphorylation on tyrosine residues following ligand
binding. Phosphotyrosines within activated receptors
form binding sites for the Src homology 2 (SH2) domains
of cytoplasmic signalling proteins. One such protein, Shc,
is tyrosine phosphorylated in response to a large number
of growth factors and cytokines. Phosphorylation of Shc
on tyrosine residue Y317 allows binding to the SH2
domain of Grb2, and hence stimulation of the Ras path-
way. Shc is therefore implicated as an adaptor protein able
to couple normal and oncogenic protein-ryrosine kinases
to Ras activation. Shc itself contains an SH2 domain at its
carboxyl terminus, but the function of the amino-terminal
half of the protein is unknown.
Results: We have found that the Shc amino-terminal
region binds to a number of tyrosine-phosphorylated
proteins in v-src-transformed cells. This domain also bound
directly to the activated epidermal growth factor (EGF)
receptor. A phosphotyrosine (pY)-containing peptide
modeled after the Shc-binding site in polyoma middle T
antigen (LLSNPTpYSVMRSK) was able to compete
efficiently with the activated EGF receptor for binding to
the Shc amino terminus. This competition was dependent
on phosphorylation of the tyrosine residue within the
peptide, and was abrogated by deletion of the leucine
residue at position -5. The Shc amino-terminal domain
also bound to the autophosphorylated nerve growth fac-
tor receptor (Trk), but bound significantly less well to a
mutant receptor in which tyrosine Y490 in the receptor's
Shc-binding site had been substituted by phenylalanine.
Conclusion: These data implicate the amino-tenninal
region of Shc in binding to activated receptors and other
tyrosine-phosphorylated proteins. Binding appears to be
specific for phosphorylated tyrosine residues within the
sequence NPXpY, which is conserved in many Shc-
binding sites. The Shc amino-terminal region bears only
very limited sequence identity to known SH2 domains,
suggesting that it represents a new class of phospho-
tyrosine-binding modules. Consistent with this view, the
amino-terminal Shc domain is highly conserved in a
Drosophila Shc homologue. Binding of Shc to activated
receptors through its amino terminus could leave the
carboxy-terminal SH2 domain free for other interactions.
In this way, Shc may function as an adaptor protein to
bring two tyrosine-phosphorylated proteins together.
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Introduction
Many growth and differentiation factors bind to cell-
surface receptors with protein-tyrosine kinase activity [1].
Such ligand binding results in dimerization and activation
of the receptor, possibly as a result of receptor cross-
phosphorylation [2,3]. A number of autophosphorylation
sites in activated receptors, usually located outside of the
catalytic domain, function as binding sites for the Src
homology 2 (SH2) domains of cytoplasmic-signalling or
adaptor proteins [4,5]. Thus, growth factors induce
autophosphorylation of receptors at specific sites, and
hence recruitment of specific SH2-containing molecules
to the activated receptor.
SH2 domains were originally identified as functional
signalling elements that are conserved among non-
receptor protein-tyrosine kinases, and were later found
to bind to phosphorylated tyrosine residues [6-9]. The
specificity of these SH2-mediated interactions is apparently
determined by the amino-acid sequence carboxy-terminal
to the phosphorylated tyrosine residue [10-15]. A wide
range of SH2-containing signalling and adaptor molecules
with distinct biochemical and biological activities have
been identified [4,5]. The SH2 domains of these signalling
proteins control not only their assoeiation with activated
receptors, but also their interactions with other intra-
cellular phosphoproteins. These interactions regulate the
subcellular localization, phosphorylation and enzymatic
activity of intracellular signalling proteins, thereby stimu-
lating biochemical pathways that elicit cellular responses
to growth factor stimulation.
Shc was identified in a screen for human cDNAs
encoding novel SH2 domain-containing proteins [16].
Shc proteins contain a carboxy-terminal SH2 domain, an
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amino-terminal domain and a central proline- and
glycine-rich domain with some homology to ol collagen.
Anti-Shc antisera specifically recognize three proteins, of
46, 52 and 66 kD, in cell lysates, all of which are appar-
ently generated by alternative translational initiation from
the same Shc mRNA, or by alternative splicing [16].
These three Shc proteins differ from each other only by
the extent of their amino-terminal sequences.
Shc proteins are phosphorylated on serine residues in
resting cells and become phosphorylated on tyrosine
residues in response to a large number of growth factors
and cytokines [17-23]. Shc is also tyrosine-phosphorylated
in cells transformed by oncogenic tyrosine kinases such as
v-Src, v-Fps and Bcr-Abl [24,25]. The principal site of
Shc phosphorylation is on tyrosine residue Y317, within
the sequence YVNV, which forms a high-affinity bind-
ing site for the SH2 domain of the adaptor protein Grb2
[23,25,26]. Grb2 has a single SH2 domain located
between two SH3 domains [27-29], which can associate
with the Ras guanine nucleotide exchange factors,
mSosl and mSos2 [30-34]. Sos proteins, in turn, can
activate Ras by catalyzing the exchange of GTP for GDP
bound to Ras. Shc overexpression induces fibroblast
transformation and Ras-dependent neurite outgrowth in
PC12 cells; in addition, tyrosine-phosphorylation of Shc
appears to be important for Ras activation following
stimulation by growth factors [23,26,35]. The ability of
tyrosine-phosphorylated Shc to bind to Grb2 and Sos
provides a mechanism by which it might stimulate the
Ras/mitogen-activated protein (MAP) kinase pathway.
The carboxy-terminal SH2 domain of Shc can bind
to phosphotyrosine (pY)-containing proteins. The
binding specificity of the Shc SH2 domain -
pY(I/E/Y)X(I/L/Y), where X is any amino acid - has
been determined by binding studies with degenerate
phosphotyrosine-containing peptides [13]. However, a
number of preferred Shc-binding sites, such as those found
in the nerve growth factor (NGF) receptor (Trk), polyoma
middle T antigen, the epidermal growth factor (EGF)
receptor and ErbB3, are characterized by the sequence
NPXpY [36-40]. Furthermore, despite evidence that the
amino-terminal region of Shc might be functionally
important (P.G. Pelicci, personal communication), no bio-
chemical activity has yet been ascribed to this Shc domain.
Results
An amino-terminal Shc domain is conserved in evolution
As an approach towards understanding the functions of Shc
proteins in signal transduction, we have recently isolated
cDNAs for mouse Shc and for a Drosophila Shc homologue
(VK-M.L, J.P.O. and TP., unpublished observations).
Comparison of the amino-acid sequences of human,
mouse and Drosophila Shc proteins shows that the carboxy-
terminal region, corresponding to the SH2 domain, has the
highest degree of sequence conservation (64 % between
human and Drosophila). The amino-terminal regions of
mammalian and Drosophila Shc proteins are also strongly
conserved, suggesting the presence of a second domain that
might be important for protein-protein interactions (Fig.
1). In contrast, the central region separating the amino-
terminal and SH2 domains is less well conserved.
Association of the amino-terminal Shc domain with
phosphotyrosine-containing proteins and activated
EGF receptors
To test the hypothesis that the conserved amino-terminal
Shc domain is involved in the formation of protein com-
plexes, we generated several expression vectors encoding
glutathione S-transferase (GST) fusion proteins which
included parts of the Shc amino terminus (Fig. 2a).
GST-ShcA contains the first 108 amino acids of Shc,
starting at the initiating methionine of the p52 isoform
[16]; GST-ShcB and GST-ShcC contain Shc residues
1-225 and residues 1-307, respectively; GST-Shc+
Fig. 1. Comparison of the amino-acid sequences of mammalian and Drosophila Shc homologues identifies a novel, conserved
amino-terminal domain spanning residues 40-205. Residues identical in the three sequences are shaded.
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Fig. 2. Fusion proteins containing the amino terminus of Shc bind to phosphotyrosine-containing proteins in v-src-transformed cells.(a) The Shc amino terminus was expressed as a series of GST-fusion proteins: GST-ShcA contains p52 s hc residues 1-108; GST-ShcB
contains p52 s hc residues 1-225; GST-ShcC contains p52 s hc residues 1-307; GST-Shc+ contains p52 s hc residues 280-473, including
the SH2 domain. (b) GST-Shc fusion proteins bind a number of phosphotyrosine-containing proteins in lysates of v-src-transformed Rat-
2 fibroblasts (Rat-2 v-src cells). Approximately equal amounts of GST (lane 1), GST-ShcA (lane 2), GST-ShcB (lane 3), GST-ShcC (lane
4), and GST-Shc+ (lane 5), bound to glutathione-Sepharose beads, were incubated with Triton X100 lysates from Rat-2 v-src cells. An
anti-Shc immunoprecipitate (lane 6) is shown for comparison. Bound proteins were analyzed by anti-phosphotyrosine immunoblotting.
contains the carboxy-terminal 193 amino-acid residues number of phosphotyrosine-containing proteins (Fig.
of Shc, which include the SH2 domain, and was used as. 2b), whereas neither GST nor GST-ShcA showed sig-
a control. These purified proteins were tested for their nificant binding activity. Although GST-Shc+ ,
ability to bind proteins from v-src-transformed cells. containing the SH2 domain, also associated with
Lysates from v-src-transformed Rat-2 cells were incu- tyrosine-phosphorylated proteins, these appeared to be
bated with approximately equal amounts of GST, different from those bound by the Shc amino terminus,
GST-ShcA, GST-ShcB, GST-ShcC or GST-Shc+ , based on their mobilities during SDS-polyacrylamide
bound to glutathione beads. Bound proteins were ana- gel electrophoresis. The amino terminus and the
lyzed by immunoblotting with an anti-phosphotyrosine SH2 domain appeared to bind complementary sets of
antiserum, and Shc immunoprecipitate was analyzed in phosphoproteins, together accounting for most of the
parallel (Fig. 2b). GST-ShcB and GST-ShcC, containing phosphotyrosine-containing proteins present in the Shc
the entire conserved amino-terminal region, bound a immunoprecipitates (Fig. 2b).
Fig. 3. The conserved Shc amino-
terminal domain binds a number of
phosphotyrosine-containing proteins,
including the EGF receptor, in lysates of
EGF-stimulated cells. (a) Triton X100
lysates from control (lanes 1, 3, 5, 7, 9,
11) and EGF-stitnulated (lanes 2, 4, 6, 8,
10, 12) HER14 cells were incubated
with approximately equal amounts of
GST (lanes 1, 2), GST-ShcA (lanes 3, 4),
GST-ShcB (lanes 5, 6), GST-ShcC (lanes
7, 8), and GST-Shc+ (lanes 9, 10) bound
to glutathione-Sepharose beads. Shc
immunoprecipitates were analyzed in
parallel (lanes 11, 12). Lanes 13 and 14
show a longer exposure of lanes 9 and
10. Bound proteins were analyzed by
anti-phosphotyrosine immunoblotting.
(b) The blot obtained in an experiment
parallel to that shown in (a) was probed
with an anti-EGF receptor antiserum.
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To investigate whether binding to the Shc amino-terminal
region could be induced by growth factor treatment, the
GST-Shc fusion proteins were incubated with lysates of
quiescent and EGF-stimulated NIH3T3 cells over-
expressing EGF receptors (HER14 cells). Bound proteins
were analyzed by anti-phosphotyrosine immunoblotting
and Shc immunoprecipitates were analyzed in parallel.
Little binding activity was exhibited by any of the Shc
fusion proteins towards proteins present in lysates of
unstimulated cells (Fig. 3a). However, the GST-ShcB,
GST-ShcC and GST-Shc+ fusion proteins all associated
with a number of phosphotyrosine-containing proteins in
lysates of EGF-stimulated cells, whereas none bound to
GST or GST-ShcA. A phosphoprotein with a molecular
weight of-175 kD that bound to GST-ShcB, GST-ShcC
and GST-Shc+ in lysates of EGF-stimulated cells was also
present in the parallel Shc immunoprecipitates. This pro-
tein was identified as the autophosphorylated EGF recep-
tor by probing the blot from a parallel experiment with an
anti-EGF receptor antiserum (Fig. 3b). No EGF receptor
molecules were bound by the Shc amino-terminal or
SH2 domains prior to EGF stimulation. These results
suggest that the conserved Shc amino-terminal domain
binds specifically to the EGF receptor in lysates from
EGF-stimulated cells. In order to test whether the
platelet-derived growth factor (PDGF) receptor could also
associate with the Shc amino terminus following receptor
activation, lysates of quiescent and PDGF-stimulated
Rat-2 fibroblasts were incubated with GST-Shc fusion
proteins: no binding of activated PDGF receptors to the
Shc amino terminus was observed (data not shown).
The amino-terminal Shc domain binds directly to the
autophosphorylated EGF receptor
To investigate whether the Shc amino-terminal region
binds directly or indirectly to the activated EGF. receptor,
Fig. 4. The Shc amino-terminal domain binds directly to the EGF
receptor. (a) Triton X100 lysates (lanes 1-3) and lysates boiled in
the presence of SDS (lanes 4-6), from control (lanes 2 and 4) or
EGF-stimulated (lanes 1, 3, 5, and 6) HER14 cells, were incu-
bated with approximately equal amounts of GST (lanes 1 and 6)
or GST-ShcB (lanes 2-5) bound to glutathione-Sepharose beads.
Bound proteins were analyzed by anti-EGF receptor
immunoblotting. (b) Anti-EGF receptor immunoprecipitates from
control (lane 1) and EGF-stimulated (lane 2) HER14 cells were
resolved by SDS-PAGE and transferred to a PVDF membrane.
The membrane was incubated with a bacterial lysate containing
GST-ShcB, and was subsequently probed for the presence of
bound GST-ShcB with an anti-GST antiserum.
lysates were boiled in the presence of 0.5 % SDS to
denature all proteins and thereby disrupt protein-protein
interactions. Boiled lysates were diluted and incubated
with the GST-ShcB fusion protein; the resulting
complexes were separated and probed for the presence of
the EGF receptor by immunoblotting (Fig. 4a). Activated
EGF receptors present in boiled lysates of EGF-stimulated
HER14 cells were still able to bind to the Shc amino-
terminal region, although less efficiently compared to
receptors from lysates containing Triton X100 as the only
detergent. In an independent approach, EGF receptors
were immunoprecipitated from control and EGF-stimu-
lated HER14 cells, resolved by SDS-polyacrylamide gel
Fig. 5. A phosphopeptide containing an NPXpY motif competes efficiently for binding of GST-ShcB to the activated EGF receptor.
(a) GST-ShcB bound to glutathione-Sepharose beads was incubated with Triton X100 lysates from control (lane 1) and EGF-stimu-
lated (lanes 2-5) HER14 cells in the absence (lanes 1,2) or the presence (lanes 3-5) of 1, 10, and 100 p.M of a phosphopeptide
based on the sequence around the Shc-binding site (Y250) in polyoma middle T antigen (LLSNPTpYSVMRSK). (b) GST-ShcB bound
to glutathione-Sepharose beads was incubated with Triton X100 lysates from control (lane 1) and EGF-stimulated (lanes 2-5) HER14
cells in the absence (lanes 1,2) or the presence (lanes 3-5) of 10 pM competing peptides - the phosphorylated polyoma middle T
1 3mer (lane 3); the unphosphorylated polyoma middle T 1 3mer (lane 4); or the irrelevant phosphotyrosine-containing control peptide
GMKIpYIDPFTpYEDPNEAVK (lane 5). (c) GST-ShcB bound to glutathione-Sepharose beads was incubated with Triton X100 lysates
from EGF-stimulated HER14 cells in the absence (lane 1) or the presence (lanes 2-8) of 10 pM of a series of sequentially truncated
phosphotyrosine-containing peptides based on the sequence around Y250 in polyoma middle T (LLSNPTpYSVMRSK) - the 13mer
starting at L_6 (lane 2); the 1 2mer starting at L_5 (lane 3); the 11 mer starting at S4 (lane 4); the 1 Omer starting at N_3 (lane 5); the 9mer
starting at P-2 (lane 6); the 8mer starting at T_1 (lane 7); and the 7mer starting at the phosphotyrosine, pY (lane 8).
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electrophoresis and transferred electrophoretically to a
PVDF membrane. This membrane was incubated for
60 minutes with lysates of Escherichia coli cells expressing
GST-ShcB. After incubation with this bacterial lysate,
the membrane was washed and then probed for the pres-
ence of GST-ShcB with an anti-GST antiserum (Fig.
4b). The results indicate that GST-ShcB is able to bind
directly to EGF receptors from EGF-stimulated HER14
cells. Only weak binding to the EGF receptors from
unstimulated cells was observed. This may be due to a
low level of receptor activation in resting cells resulting
from overexpression of the receptor, as receptors from
quiescent cells contained some phosphotyrosine (data not
shown). These data clearly show that the Shc amino-
terminal region binds to the activated EGF receptor,
and that binding results from direct recognition of the
autophosphorylated receptor.
A phosphopeptide containing an NPXpY motif competes
with the activated EGF receptor for binding to the
amino-terminal Shc region
As Shc proteins bind in vivo to tyrosine residues within
the sequence NPXpY, of which two are present in the
EGF receptor, it is possible that the Shc amino-terminal
region recognizes such sequences. To investigate this
possibility, lysates from EGF-stimulated cells were incu-
bated with GST-ShcB in the presence of increasing
amounts of a phosphopeptide containing an NPXpY
motif. This peptide corresponds to the Shc-binding site
of the polyoma middle T antigen, centered on tyrosine
residue Y250 (LLSNPTpYSVMRSK). This peptide
competed efficiently for binding of the fusion protein to
the EGF receptor (Fig. 5a). An approximately 50 % reduc-
tion in binding was observed in the presence of 1 IM
peptide. Neither unphosphorylated polyoma middle T
peptide, nor an irrelevant phosphotyrosine-containing
peptide (GMKIpYIDPFTpYEDPNEAVK), competed
with GST-ShcB for binding to the EGF receptor (Fig. 5b).
This indicates that the binding of GST-ShcB to the EGF
receptor depends on the presence of a phosphorylated
tyrosine residue within a specific amino-acid sequence.
To investigate further the contribution of peptide
residues amino-terminal to the phosphorylated tyrosine
residue to binding by the amino-terminal Shc region, a
series of polyoma middle T peptides, sequentially trun-
cated at the amino terminus one residue at a time, were
tested for their ability to compete with the auto-
phosphorylated EGF receptor for binding to GST-ShcB.
The original phosphorylated 13mer, which includes six
residues amino-terminal to the phosphotyrosine, and the
12mer with five amino-terminal residues, but none of
the shorter peptides, competed efficiently with the EGF
receptor for binding to GST-ShcB (Fig. 5c). These
results, summarized in Table 1, suggest that the binding
of a peptide to the amino-terminal region of Shc
depends on residues amino-terminal to the phospho-
tyrosine. The aliphatic leucine five residues amino-
terminal to the phosphotyrosine (the -5 position) appears
to be important for binding.
The amino-terminal Shc domain binds specifically to
tyrosine 490 in the NGF receptor
To test whether the receptor-binding activity of the
amino-terminal Shc domain has a more general role, we
assessed its ability to bind to the nerve growth factor
receptor, Trk, which is known to associate with Shc in
vivo. Several autophosphorylation sites have been identi-
fied in Trk, of which tyrosine residue Y490 functions as
the principal Shc-binding site, and Y785 is required for
binding to phospholipase C y (PLCy) [40,41]. Wild-type
Trk, as well as mutants in which tyrosine residues Y490
and Y785 were substituted by phenylalanines (F490 and
F785, respectively) and kinase-inactive Trk mutants were
expressed using the baculovirus expression system in Sf9
cells. Approximately equal amounts of receptors were
immunoprecipitated from lysates of 1.5 x 106 cells,
Fig. 6. Binding of the amino-terminal Shc domain to tyrosine
residue Y490 in Trk. Trk immunoprecipitates from 1.5 x 106 Sf9
cells expressing wild-type (Wt, lanes 1, 2), F490 (lanes 3, 4),
F785 (lanes 5, 6) and kinase-inactive (N538, lanes 7,8) Trk were
autophosphorylated in vitro and subsequently incubated with
bacterial lysates containing equal amounts of GST-ShcB (lanes 1,
3, 5, 7) or GST-Shc+ (lanes 2, 4, 6, 8). Bound proteins were
analyzed by immunoblotting with an anti-GST antiserum.
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autophosphorylated in vitro in the presence of ATP and
subsequently incubated with bacterial lysates containing
equal amounts of GST-ShcB or GST-Shc+ . GST-fusion
proteins that bound to activated Trk were analyzed by
immunoblotting with an anti-GST antiserum. GST-ShcB
bound efficiently to autophosphorylated wild-type Trk
and to the F785 mutant, but poorly to the F490 mutant
and kinase-inactive Trk (Fig. 6).GST-Shc+ polypeptide
did not bind appreciably to any of the autophosphorylated
Trk receptors tested (Fig. 6).
These results indicate that the isolated Shc amino-terminal
domain binds specifically to the tyrosine 490 Trk
autophosphorylation site, reflecting the specificity of Shc
binding in vivo. As the Shc SH2 domain apparently plays
a lesser role in binding to activated Trk, it is likely that
the amino-terminal domain is responsible for binding of
Shc to Trk in vivo, an interaction which appears to be
important in coupling nerve growth factor stimulation to
neurite outgrowth in PC12 cells [42,43].
Discussion
Analysis of the amino-acid sequences of human, mouse
and Drosophila Shc homologues indicates that, in addition
to the carboxy-terminal SH2 domain, a second highly
conserved domain of approximately 160 amino acids is
located at the amino terminus (V.K-M.L., J.P.O. and T.P.,
unpublished observations). The presence of this element
in both mammalian and Drosophila Shc suggests that it is
functionally important and might therefore represent a
module involved in protein-protein interactions.
Consistent with this possibility, the amino-terminal region
of Shc expressed as a GST-fusion protein bound a number
of unidentified phosphotyrosine-containing proteins in
v-src-transformed cells. This domain also bound specifi-
cally to the EGF receptor following stimulation with
EGF, whereas a shorter fusion protein that lacked part of
the conserved Shc sequence failed to associate with the
activated EGF receptor.
The activated EGF receptor also associated with the Shc
amino-terminal region in lysates boiled in the presence of
SDS, which disrupts previously formed protein com-
plexes. The fact that denatured EGF receptors bind less
well to this novel domain than native receptors suggests
that optimal binding may require some degree of struc-
ture. In a GST-fusion protein, the Shc amino-terminal
region also binds to EGF receptors present on PVDF
membranes. These data show that the Shc amino-terminal
region .directly recognizes the autophosphorylated EGF
receptor. The identities of phosphotyrosine-containing
polypeptides from v-src-transformed and EGF-stimulated
cells that bind to Shc are currently under investigation.
Previous work has suggested that Shc binds in vivo to sites
with a conserved motif, NPXpY, found in a variety of
receptors and cytoplasmic proteins. These include Trk,
the EGF receptor, ErbB3 and the polyoma middle T
antigen [36-40]. The Shc SH2 domain binds preferen-
tially in vitro to phosphopeptides with the sequence
pY(I/E/Y)X(I/L/M), suggesting that, like other SH2
domains, it may primarily recognize residues carboxy-
terminal to the phosphorylated tyrosine residue [13].
Furthermore, the Shc SH2 domain does not bind with
high affinity to phosphopeptides containing the sequence
NPXpY (S.E.S., unpublished observations). In contrast, a
phosphopeptide with the NPXpY motif, based on the
sequence flanking tyrosine residue Y250 of the polyoma
middle T antigen Shc-binding site, competed efficiently
with the EGF receptor for binding to the amino-
terminal Shc domain [37,38]. These results raised the
possibility that the amino-terminal Shc domain might
participate in the recognition of NPXpY sites. Such a
Shc-binding motif is found at tyrosine residue Y490 of
the Trk NGF receptor [40,42]. The Shc SH2 domain
does not bind efficiently to autophosphorylated Trk in
vitro; in contrast the amino-terminal Shc domain bound
to wild-type Trk, but not to a Trk mutant specifically
lacking the Y490 autophosphorylation site.
The activated PDGFI3 receptor does not contain any
NPXpY sequences in its cytoplasmic domain [44,45] and
does not bind to the Shc amino-terminus in vitro,
although it does associate with the Shc SH2 domain [46].
These results indicate that the Shc amino-terminal region
directly recognizes phosphotyrosines, but unlike SH2
domains it may require specific residues amino-terminal
to the phosphotyrosine for high-affinity binding.
Consistent with this possibility, deletion of the leucine
residue at the -5 position from the polyoma middle T
phosphopeptide completely abolished its ability to com-
pete for binding of the EGF receptor to the Shc amino-
terminal region. We have obtained identical results when
the series of polyoma middle T phosphopeptides were
assayed directly for binding to the Shc amino-terminal
Fig. 7. Shc mediates multiple phosphotyrosine-dependent
protein-protein interactions. Shc contains two domains that bind
phosphotyrosine - the PTB domain and an SH2 domain. The
PTB domain apparently recognizes phosphotyrosine in the con-
text of amino-terminal residues (with consensus sequence
NPXpY), while the SH2 domain recognizes phosphotyrosine and
carboxy-terminal residues. The PTB and SH2 domains of Shc
may potentially bind distinct sites on the same protein - the
activated EGF receptor for example - or might associate with
two different polypeptides. In addition, phosphorylation of Shc at
tyrosine Y317 creates a binding site for the Grb2 SH2 domain.
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domain by surface plasmon resonance, using a Biacore
(unpublished observations). This suggests that the Shc
amino-terminal domain recognizes at least five residues
amino-terminal to the phosphorylated tyrosine. Inter-
estingly, a non-polar residue is present at the -5 position
of most Shc binding sites identified thus far [38].
These results raise the possibility that Shc has two
receptor-binding domains - a conventional carboxy-
terminal SH2 domain required for association with the
PDGF receptor and a novel, amino-terminal phospho-
tyrosine-binding (PTB) domain that binds receptors with
NPXpY motifs, such as Trk (Fig. 7). The activated EGF
receptor binds stably to both the amino- and carboxy-
terminal Shc domains in vitro, which may account for the
very potent phosphorylation of Shc observed in cells or
animals stimulated with EGF [16,20]. In principle, the
two phosphotyrosine-binding modules of Shc might also
recognize sites on different proteins, which would then
be brought into a common complex.
The results presented here suggest that the amino-
terminal Shc domain behaves functionally as an SH2
domain, in that it directly recognizes specific phosphoty-
rosine-containing sites. At first glance, there is no obvi-
ous sequence relationship between the amino-terminal
Shc region and known SH2 domains. However, a
sequence can be identified immediately amino-terminal
to the p46 initiation site of Shc, WLHPND, which is
reminiscent of the amino termini of conventional SH2
domains (for example, the Syp amino-terminal SH2
domain begins with WFHPNI) [47]. This is followed by
the sequence YLVR, which resembles the motif
F/YLVR found in many SH2 domains and contains the
only invariant SH2 residue, arginine B135 [14]. In SH2
domains, this arginine lies at the base of the positively-
charged phosphotyrosine-binding pocket and forms
hydrogen bonds with the phosphate oxygens. Indeed, the
Shc amino-terminal region has a substantial number of
basic residues that are conserved in the Drosophila hom-
ologue. Therefore, it is possible that the Shc amino-ter-
minal domain has a phosphotyrosine-binding pocket that
resembles that of SH2 domains, but differs in the rest of
its ligand-binding surface. This may account for the
apparent ability of Shc to bind tyrosine phosphorylation
sites with conserved features involving residues amino-
terminal to the phosphotyrosine. The mechanism by
which the Shc amino-terminal region recognizes such
sites awaits further investigation.
The precise extent of the Shc amino-terminal domain
required for binding to the activated EGF receptor and
other tyrosine phosphorylated proteins is not yet defined.
However, la fusion protein containing the first 108
residues of p52Shc did not bind the EGF receptor,
whereas a protein containing the first 225 residues bound
tightly to the receptor. Our data are in agreement with
two recent studies defining a novel Shc phosphotyrosine-
binding domain between residues 46 and 208 of p52shc
[48,49]. The region of high sequence identity between
mammalian and Drosophila Shc proteins spans residues
40-205 of p52shc, which correspond roughly to the
receptor-binding domain (see Fig. 1). We have recently
identified a sequence closely related to those found at the
amino-terminal regions of mammalian and Drosophila
Shc in a distinct mouse protein (T. Saxton, J. O'Bryan
and T.P., unpublished observations), suggesting that this
novel receptor-binding domain might be of general
importance in signal transduction.
Conclusions
By comparing the amino-acid sequences of mammalian
and Drosophila homologs, we have identified a conserved
domain at the amino terminus of Shc. This novel domain
binds phosphotyrosine-containing proteins in v-src-
transformed and EGF-stimulated fibroblasts. One of the
proteins bound in lysates from EGF-stimulated fibroblasts
is the EGF receptor itself. Binding appears to be direct
and specific for phosphorylated tyrosine residues within
the sequence NPXpY, which is conserved in many Shc
binding sites. An aliphatic amino acid five residues
amino-terminal of the phosphotyrosine was also shown
to be important for high affinity binding. Binding exper-
iments with the NGF receptor, which contains only one
well-defined Shc-binding site, suggests that the Shc
amino-terminal domain may be important for its interac-
tion with activated protein-tyrosine kinase receptors in
vivo. The Shc amino-terminal region has only limited
sequence identity to known SH2 domains, suggesting
that it represents a new phosphotyrosine-binding mod-
ule. The binding of Shc to activated receptors through its
amino terminus, which recognises phosphotyrosine in
the context of amino-terminal residues, could leave the
carboxy-terminal SH2 domain free for other interactions.
Thus, Shc may function as an adaptor protein that brings
together two tyrosine-phosphorylated proteins.
Materials and methods
Cells lines and antibodies
NIH3T3 cells overexpressing human EGF receptor (HER14
cells) [50] were grown in Dulbecco-Vogt modified Eagle's
medium (DMEM) containing 10 % fetal bovine serum (FBS)
and 400 Ag ml-1 G418; v-src transformed Rat-2 cells [51] were
grown in DMEM containing 10 % FBS. A polyclonal anti-Shc
antiserum was raised against a GST-Shc SH2 fusion protein. A
polyclonal anti-phosphotyrosine antiserum was raised and
affinity purified as described [52]. An anti-EGF receptor mon-
oclonal antibody used for immunoprecipitations was purchased
from UBI (Lake Placid, New York, USA). Polyclonal
anti-EGF receptor antisera were used for immunoblotting.
GST-fusion proteins
pGEX GST-Shc fusion constructs were generated by PCR
subcloning of human p52s hc cDNA fragments encoding
residues 1-108 (GST-ShcA), 1-225 (GST-ShcB) or 1-307
(GST-ShcC) in pGEX4T-2. The PCR products were
sequenced to ensure fidelity. GST-Shc+ contains p52Shc
residues 280-473 [26]. Expression of fusion proteins was
A novel Shc domain that binds phosphotyrosine motifs van
induced by incubation in the presence of 100 JtM IPTG for
several hours at 30 C. Bacteria were lysed by sonication in
phosphate buffered saline (PBS) containing 1 mM DTT, 1 mM
Benzamidine, 10 .g ml-1 Aprotinin and 10 pg m-1
Leupeptin. Triton-X 100 was added to a final concentration of
1 %, nuclei were removed by centrifugation for 10 min at
10 000 xg at 4 °C, and fusion proteins were purified by bind-
ing to glutathione-Sepharose. Glutathione-Sepharose beads
were collected by centrifugation and washed five times with
PBS containing 1 % Triton X100, 1 mM DTT and 1 mM
Benzamidine. Fusion proteins were stored at 4 C bound to
beads in PBS, containing 1 % Triton X100, 1 mM DTT,
1 mM Benzamidine, 0.02 % sodium azide and 10 % glycerol.
Immunoprecipitation and immunoblotting
Cells were grown to subconfluence on 10 cm tissue culture
dishes. If cells were to be stimulated with EGF, they were
starved for 14-16 h in DMEM containing 0.5 % FBS and
20 mM HEPES pH 7.2. Control cells or cells stimulated with
100 ng ml-1 EGF for 5 min at 37 °C were rinsed twice with
cold PBS and lysed in 1 ml 50 mM HEPES pH 7.5, 150 mM
NaCl, 10 % glycerol, 1 % Triton X100, 1.5 mM MgCI2 1 mM
EGTA, 100 mM NaF, 10 mM sodium pyrophosphate, 500 pM
sodium vanadate, 1 mM PMSF, 10 pg ml-' Aprotinin and
10 pg m1-1 Leupeptin (PLC-lysis buffer) per 10 cm tissue cul-
ture dish. Lysates were cleared by centrifugation at 10 000 rpm
in a microcentrifuge at 4 C, incubated with 5 pl polyclonal
antiserum or 1 g monoclonal antibody for 1 h on ice and sub-
sequently with 100 1 10 % Protein A-Sepharose or anti-mouse
IgG-Sepharose for 1 h at 4 °C on an agitator. Sepharose beads
were collected by centrifugation and washed four times with
PLC-lysis buffer. Immunoprecipitates were boiled for 3 min in
62.5 mM Tris/Cl pH 6.8, 10 % glycerol, 5 % P-mercapto-
ethanol, 5 mM DTT, 2.3 % SDS, and 0.025 % bromophenol
blue (SDS-sample buffer) and resolved by SDS-PAGE.
To disrupt previously formed protein-protein complexes, cells
from a 10 cm tissue culture dish were collected and boiled for
3 min in 200 I 10 mM sodium phosphate, 0.5 % SDS, 1 mM
EDTA and 1 mM DTT. After boiling, the lysates were diluted
in 800 l 50 mM sodium phosphate, 150 mM aCl, 1 %
Nonidet P40, 1 % sodium deoxycholate, 2 mM EDTA,
50 mM NaF and 100 pM sodium orthovanadate.
For in vitro binding studies, fibroblast cell lysates were
incubated for 1 h at 4 °C on a rocker with 25 1 glutathione-
Sepharose beads containing 5-10 pzg of fusion protein. Beads
were washed four times with PLC-lysis buffer and bound
proteins were analyzed by SDS-PAGE and immunoblotting.
For immunoblotting, proteins were transferred to PVDF
membranes using a Biorad semi-dry blotting apparatus at
50 mA per gel for 60 min at room temperature. Membranes
were blocked for h at room temperature in 10 mM Tris/CI
pH 7.4, 150 mM NaCl, 0.2 % Tween 20 (TBST) containing
5 % dried milk and incubated with a 1:200 dilution of poly-
clonal antisera in TBST + 5 % milk for 1 h at room tempera-
ture. Blots were washed 2 x 10 min with TBST and 2 x 5 min
with 10 mM Tris/Cl pH 7.4 and 150 mM NaCl (TBS).
Membranes were then incubated for 1 h with HRP-Protein A
(Biorad, Hercules, California 94547, USA) diluted 1:10 000 in
TBST and washed as before. Reactive proteins were visualized
by ECL (Amersham Canada, Oakville, Ontario, L6L 5T7). For
immunoblotting with anti-phosphotyrosine antiserum, mem-
branes were blocked with TBST containing 5 % bovine serum
albumin (BSA) followed by an incubation with the antiserum
diluted in TBST + 5 % BSA. Washes and detection were done
exactly as described for other antisera.
For binding of fusion proteins to EGF receptors immobilized
onto PVDF membranes, membranes were blocked by incuba-
tion for h at 4 C in TBST containing 5 % BSA and subse-
quently incubated for 1 h at 4 C with 3 ml bacterial lysate
containing 2 g of GST-ShcB diluted 1:3 in TBST + 5 %
BSA. Bound proteins were detected by immunoblotting with
an anti-GST antiserum.
Baculovirus expression of Trk proteins and in vitro
binding to bacterially expressed GST-Shc fusion proteins
Wild-type and mutant Trk proteins were expressed using a
baculovirus expression system in Sf9 cells, immunoprecipitated
and phosphorylated in vitro in the presence of 100 nM ATP as
described before [42]. Following in vitro autophosphorylation,
immunoprecipitated receptors obtained from 1.5 x 106 cells
were incubated with 1 ml bacterial lysate, containing approxi-
mately 5 g GST-Shc fusion protein, for 1 h at 4 C;
immunocomplexes were washed four times with PLC-lysis
buffer and analyzed by immunoblotting with a polyclonal
anti-GST serum.
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